newsfilter
← Latest News
GlobeNewswire·

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be presented in oral